Expedeon
Cambridge
About Expedeon
Expedeon is an expert in cutting-edge innovative reagents and services for life sciences and diagnostics, with application across workflows including: protein electrophoresis; liquid biopsy; whole genome amplification; antibody- and protein-labeling; and immunoassay development. Our cutting-edge offerings include off-the-shelf products, and custom services, supporting scientists from academia through to commercial manufacturing across the life sciences and diagnostic industry. Expedeon’s dedicated team of experts has the flexibility to develop and supply consistently high quality products both off-the-shelf and to customer specification. We are constantly innovating to provide high quality, easy-to-use, cost-effective solutions, to minimize hands-on time for researchers. All our products are stringently QC tested, and are designed to save scientists time and costs. Expedeon is wholly owned by SYGNIS AG and has laboratory facilities and commercial sites in the UK, USA, Singapore, Germany and Spain. Expedeon provides fast, global delivery. Off-the-shelf products are available with next-day delivery and quick turnaround times are offered on custom product generation.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1,001 – 5,000
- Total funding: $6.9M
- Funding stage: M&A
- Last round: Debt Financing (Aug 2018)
- Website: expedeon.com
- Phone: +44 (0) 1223 661000
Industries & Categories
Biotechnology, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/expedeon-33974 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.